Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences Inc (NASDAQ: XBIO) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies through its DNase platform and polyxen™ technology. This page provides investors and researchers with centralized access to the company’s latest developments in cancer treatment innovation.
Find timely updates on XBIO’s clinical trial progress, strategic collaborations, and regulatory milestones. Our curated collection includes press releases about orphan-designated therapies, CAR T platform advancements, and preclinical research insights – all essential for tracking the company’s contributions to targeted cancer treatments.
Key updates cover three focus areas: clinical developments in hard-to-treat cancers, technology partnerships enhancing therapeutic efficacy, and scientific publications validating novel approaches to tumor microenvironment modulation. Bookmark this page to stay informed about Xenetic’s progress in developing next-generation biologics and combination therapies.
Xenetic Biosciences (NASDAQ: XBIO) has announced a significant collaboration with The Scripps Research Institute to advance its systemic DNase-based oncology program, aimed at treating pancreatic carcinoma and other solid tumors. This partnership will enhance the development of the DNase platform, which targets neutrophil extracellular traps (NETs), implicated in cancer progression and therapeutic resistance. Xenetic plans to initiate a first-in-human study assessing the DNase in combination with immune checkpoint inhibitors or chemotherapy. Furthermore, the agreement allows Xenetic to acquire an exclusive license for any new intellectual property resulting from the research. This collaboration is seen as a critical step towards creating much-needed therapies for challenging cancer indications.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
